BIRC5 and chronic myelogenous leukemia, BCR-ABL1 positive: JAK2 inhibitor TG101209, suppresses survivin expression at nanomolar concentrations increasing susceptibility to chemotherapy in CML and radiotherapy in lung cancer [163, 164].